ALT Latest Headlines

$75 Million Institutional Investment Bolsters Altimmune's Phase 3 Ambitions in Liver Disease

Market Chameleon (Fri, 30-Jan 8:27 AM)

Altimmune Secures $75 Million in Direct Offering to Fuel Phase 3 MASH Program

Market Chameleon (Wed, 28-Jan 7:08 AM)

FDA Breakthrough for Altimmune: Pemvidutide Shows Statistically Significant Improvements in MASH Patients

Market Chameleon (Mon, 5-Jan 10:32 AM)

ALT’s Pemvidutide Shows Significant Antifibrotic Benefits at 48 Weeks: Phase 2b Results Point Toward Phase 3 Trial

Market Chameleon (Mon, 22-Dec 10:19 AM)

ALT’s Pemvidutide Achieves Strong 48-Week Efficacy in MASH: Significant Reductions in Liver Fibrosis and Sustained Weight Loss Highlight Phase 2b Results

Market Chameleon (Fri, 19-Dec 7:06 AM)

ALT Announces CEO Transition as Pemvidutide Approaches Phase 3 Milestone

Market Chameleon (Mon, 1-Dec 8:12 AM)